/
KYTX
$8.78+$0.34 (+4.03%)live
Held · Bookmarked
1 · 0
portfolio · users
Avg position size
0.0%
of holders' portfolios
13F filers
1
institution
Market cap
$513.1M
61M shares
52-week range
$2.52 – $13.67
56% from low
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Exchange
NASDAQ
CS
Borrow rate
0.69%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-21.22
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Revenue | $5.7M | $7.0M | $0 | $0 | $0 |
| Cost of revenue | $0 | $0 | $1.7M | $2.1M | $0 |
| Gross profit | $5.7M | $7.0M | −$1.7M | −$2.1M | $0 |
| Gross margin | 100.0% | 100.0% | — | — | — |
| R&D | $25.9M | $28.4M | $48.2M | $112.5M | $133.7M |
| Operating income | −$26.3M | −$29.4M | −$62.4M | −$142.6M | −$169.8M |
| EBITDA | −$25.8M | −$27.8M | −$58.5M | −$125.2M | −$159.0M |
| Net income | −$26.4M | −$28.9M | −$60.4M | −$127.5M | −$161.3M |
| Net margin | -465.9% | -411.3% | — | — | — |
| EPS (diluted) | -1.02 | -1.12 | -0.00 | -3.33 | -3.64 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $13M | $-2.87 | $-3.07–$-2.67 | 5 |
| 2027 | $18M | $-2.94 | $-3.33–$-2.38 | 5 |
| 2028 | $53M | $-2.39 | $-2.87–$-1.69 | 3 |
| 2029 | $175M | $-3.65 | $-8.68–$-0.76 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$2.04
Price
$8.78
Implied downside
-77%
Peer comparison
Kyverna Therapeutics, Inc. Common Stock
Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.
www.kyvernatx.com- Employees
- 129
- IPO / List date
- Feb 8, 2024
- HQ
- EMERYVILLE, CA
Held by traders on TradeandTell
| Trader / Portfolio | Conviction |
|---|---|
| Robinhood — Robinhood Individualb | — |
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 367,492 | $3.2M |
Insider activity (SEC Form 4)
